Cyclohexen-1-yl-pyridin-2-yl-1h-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators

A compound according to Formula (I)

• Or a pharmaceutically acceptable salt thereof, wherein
• n is 0 or 1;
• X is N or CH;
• Z is N(H), O or CH2;
• Z1 is CR4 or N;
• R is hydrogen, C1-C4alkyl, monofluoromethyl, difluoromethyl or trifluoromethyl;
• R1 is hydrogen, halogen, C1-C4alkyl or trifluoromethyl
• R2 is piperidinyl which is N-substituted with C1-C4alkyl, C3-C6cycloalkyl, haloC1-C4alkyl, C(O)C1-C4alkyl, S(O)2C1-C4alkyl, C(O)C3-C6cycloalkyl, C(O)haloC1-C4alkyl, C(O)C1-C4alkoxy, C(O)C1-C4alkenoxy, heteroaryl or CO(O)2benzyl, wherein each cycloalkyl is optionally substituted by hydroxy and each alkyl or alkoxy is optionally substituted by hydroxyl, C1-C4alkoxy or C3-C6cycloalkyl and wherein each heteroaryl has 5 or 6 ring atoms, 1, 2 or 3 ring heteroatoms independently selected from N, O and S and is optionally substituted with 1 or 2 C1-C4alkyl substituents, which piperidinyl ring is further optionally substituted by hydroxyl;
• R3 is hydrogen, halogen or C1-C4alkyl;
• or
• R2 and R3, taken in combination, form a 5 or 6 member fused saturated azacyclic ring optionally substituted with benzyl or 5 or 6 member heteroarylmethyl, which heteroaryl has 1 or 2 ring heteroatoms independently selected from N, O and S;
• R4 is hydrogen or C1-C4alkyl;
• R5 and R5a are independently selected from the group consisting of hydrogen and C1-C4alkyl;
• or
• R5 and R5a, taken in combination form a spirocyclic cyclopropyl ring;
• and
• when n is 0, R6 and R6a are each hydrogen and when n is 1, R6 and R6a are independently selected from the group consisting of hydrogen and C1-C4alkyl;
• or
• R6 and R6a, taken in combination form a spirocyclic cyclopropyl ring.